NCT00299104 · FLOW
Participant flow
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- groups
- description
- Placebo intravenously on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8. From Week 104 participants were eligible to receive Rituximab 2 X 0.5 g or Rituximab 2 X 1.0 g every 24 weeks.
- id
- FG000
- title
- Placebo + Methotrexate
- description
- Rituximab intravenously at a dose of 0.5 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8. Subsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6
- id
- FG001
- title
- Rituximab (0.5 g x 2) + Methotrexate
- description
- Rituximab intravenously at a dose of 1.0 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8. Subsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6
- id
- FG002
- title
- Rituximab (1.0 g x 2) + Methotrexate
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 14
- group Id
- FG001
- num Subjects
- 9
- group Id
- FG002
- num Subjects
- 7
- type
- Adverse Event
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 1
- group Id
- FG002
- num Subjects
- 1
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 34
- group Id
- FG001
- num Subjects
- 13
- group Id
- FG002
- num Subjects
- 8
- type
- Insufficient therapeutic response
- reasons
- group Id
- FG000
- num Subjects
- 9
- group Id
- FG001
- num Subjects
- 8
- group Id
- FG002
- num Subjects
- 8
- type
- Failure to return
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 2
- group Id
- FG002
- num Subjects
- 0
- type
- Violation of selection criteria
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 1
- group Id
- FG002
- num Subjects
- 0
- type
- Protocol Violation
- reasons
- group Id
- FG000
- num Subjects
- 9
- group Id
- FG001
- num Subjects
- 2
- group Id
- FG002
- num Subjects
- 2
- type
- Refused treatment
- reasons
- group Id
- FG000
- num Subjects
- 14
- group Id
- FG001
- num Subjects
- 19
- group Id
- FG002
- num Subjects
- 9
- type
- Withdrew consent
- reasons
- group Id
- FG000
- num Subjects
- 106
- group Id
- FG001
- num Subjects
- 120
- group Id
- FG002
- num Subjects
- 137
- type
- Administrative reasons
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 251
- group Id
- FG001
- num Subjects
- 252
- group Id
- FG002
- num Subjects
- 252
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 249
- group Id
- FG001
- num Subjects
- 249
- group Id
- FG002
- num Subjects
- 250
- type
- Safety/ITT: Received Study Drug
- achievements
- group Id
- FG000
- num Subjects
- 227
- group Id
- FG001
- num Subjects
- 240
- group Id
- FG002
- num Subjects
- 241
- type
- Completed Week 24
- achievements
- group Id
- FG000
- num Subjects
- 213
- group Id
- FG001
- num Subjects
- 227
- group Id
- FG002
- num Subjects
- 232
- type
- Completed Week 52
- achievements
- group Id
- FG000
- num Subjects
- 178
- group Id
- FG001
- num Subjects
- 213
- group Id
- FG002
- num Subjects
- 216
- type
- Completed Week 104
- achievements
- comment
- Completed Week 152
- group Id
- FG000
- num Subjects
- 62
- group Id
- FG001
- num Subjects
- 77
- group Id
- FG002
- num Subjects
- 80
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 189
- group Id
- FG001
- num Subjects
- 175
- group Id
- FG002
- num Subjects
- 172
- type
- NOT COMPLETED
- title
- Treatment Period
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 3
- group Id
- FG001
- num Subjects
- 2
- group Id
- FG002
- num Subjects
- 1
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 9
- group Id
- FG001
- num Subjects
- 11
- group Id
- FG002
- num Subjects
- 20
- type
- Lost to Follow-up
- reasons
- group Id
- FG000
- num Subjects
- 16
- group Id
- FG001
- num Subjects
- 21
- group Id
- FG002
- num Subjects
- 11
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 27
- group Id
- FG001
- num Subjects
- 7
- group Id
- FG002
- num Subjects
- 5
- type
- Administrative reasons
- milestones
- achievements
- comment
- All participants who received treatment were to enter SFU even if withdrawn during treatment period.
- group Id
- FG000
- num Subjects
- 184
- comment
- All participants who received treatment were to enter SFU even if withdrawn during treatment period.
- group Id
- FG001
- num Subjects
- 212
- comment
- All participants who received treatment were to enter SFU even if withdrawn during treatment period.
- group Id
- FG002
- num Subjects
- 213
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 129
- group Id
- FG001
- num Subjects
- 171
- group Id
- FG002
- num Subjects
- 176
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 55
- group Id
- FG001
- num Subjects
- 41
- group Id
- FG002
- num Subjects
- 37
- type
- NOT COMPLETED
- title
- Safety Follow-Up (SFU) Period
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 1
- group Id
- FG002
- num Subjects
- 0
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 2
- group Id
- FG001
- num Subjects
- 2
- group Id
- FG002
- num Subjects
- 2
- type
- Lost to Follow-up
- reasons
- group Id
- FG000
- num Subjects
- 2
- group Id
- FG001
- num Subjects
- 4
- group Id
- FG002
- num Subjects
- 8
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 2
- group Id
- FG002
- num Subjects
- 2
- type
- Administrative reasons
- milestones
- achievements
- comment
- Only participants with CD19+ B-cell counts below baseline level or less than 80 cells/microliter.
- group Id
- FG000
- num Subjects
- 34
- comment
- Only participants with CD19+ B-cell counts below baseline level or less than 80 cells/microliter.
- group Id
- FG001
- num Subjects
- 40
- comment
- Only participants with CD19+ B-cell counts below baseline level or less than 80 cells/microliter.
- group Id
- FG002
- num Subjects
- 51
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 29
- group Id
- FG001
- num Subjects
- 31
- group Id
- FG002
- num Subjects
- 39
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 5
- group Id
- FG001
- num Subjects
- 9
- group Id
- FG002
- num Subjects
- 12
- type
- NOT COMPLETED
- title
- Extended Safety Follow-Up (ESFU) Period
Complete source fields
- groups
- description
- Placebo intravenously on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8. From Week 104 participants were eligible to receive Rituximab 2 X 0.5 g or Rituximab 2 X 1.0 g every 24 weeks.
- id
- FG000
- title
- Placebo + Methotrexate
- description
- Rituximab intravenously at a dose of 0.5 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8. Subsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6
- id
- FG001
- title
- Rituximab (0.5 g x 2) + Methotrexate
- description
- Rituximab intravenously at a dose of 1.0 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8. Subsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6
- id
- FG002
- title
- Rituximab (1.0 g x 2) + Methotrexate
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 14
- group Id
- FG001
- num Subjects
- 9
- group Id
- FG002
- num Subjects
- 7
- type
- Adverse Event
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 1
- group Id
- FG002
- num Subjects
- 1
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 34
- group Id
- FG001
- num Subjects
- 13
- group Id
- FG002
- num Subjects
- 8
- type
- Insufficient therapeutic response
- reasons
- group Id
- FG000
- num Subjects
- 9
- group Id
- FG001
- num Subjects
- 8
- group Id
- FG002
- num Subjects
- 8
- type
- Failure to return
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 2
- group Id
- FG002
- num Subjects
- 0
- type
- Violation of selection criteria
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 1
- group Id
- FG002
- num Subjects
- 0
- type
- Protocol Violation
- reasons
- group Id
- FG000
- num Subjects
- 9
- group Id
- FG001
- num Subjects
- 2
- group Id
- FG002
- num Subjects
- 2
- type
- Refused treatment
- reasons
- group Id
- FG000
- num Subjects
- 14
- group Id
- FG001
- num Subjects
- 19
- group Id
- FG002
- num Subjects
- 9
- type
- Withdrew consent
- reasons
- group Id
- FG000
- num Subjects
- 106
- group Id
- FG001
- num Subjects
- 120
- group Id
- FG002
- num Subjects
- 137
- type
- Administrative reasons
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 251
- group Id
- FG001
- num Subjects
- 252
- group Id
- FG002
- num Subjects
- 252
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 249
- group Id
- FG001
- num Subjects
- 249
- group Id
- FG002
- num Subjects
- 250
- type
- Safety/ITT: Received Study Drug
- achievements
- group Id
- FG000
- num Subjects
- 227
- group Id
- FG001
- num Subjects
- 240
- group Id
- FG002
- num Subjects
- 241
- type
- Completed Week 24
- achievements
- group Id
- FG000
- num Subjects
- 213
- group Id
- FG001
- num Subjects
- 227
- group Id
- FG002
- num Subjects
- 232
- type
- Completed Week 52
- achievements
- group Id
- FG000
- num Subjects
- 178
- group Id
- FG001
- num Subjects
- 213
- group Id
- FG002
- num Subjects
- 216
- type
- Completed Week 104
- achievements
- comment
- Completed Week 152
- group Id
- FG000
- num Subjects
- 62
- group Id
- FG001
- num Subjects
- 77
- group Id
- FG002
- num Subjects
- 80
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 189
- group Id
- FG001
- num Subjects
- 175
- group Id
- FG002
- num Subjects
- 172
- type
- NOT COMPLETED
- title
- Treatment Period
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 3
- group Id
- FG001
- num Subjects
- 2
- group Id
- FG002
- num Subjects
- 1
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 9
- group Id
- FG001
- num Subjects
- 11
- group Id
- FG002
- num Subjects
- 20
- type
- Lost to Follow-up
- reasons
- group Id
- FG000
- num Subjects
- 16
- group Id
- FG001
- num Subjects
- 21
- group Id
- FG002
- num Subjects
- 11
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 27
- group Id
- FG001
- num Subjects
- 7
- group Id
- FG002
- num Subjects
- 5
- type
- Administrative reasons
- milestones
- achievements
- comment
- All participants who received treatment were to enter SFU even if withdrawn during treatment period.
- group Id
- FG000
- num Subjects
- 184
- comment
- All participants who received treatment were to enter SFU even if withdrawn during treatment period.
- group Id
- FG001
- num Subjects
- 212
- comment
- All participants who received treatment were to enter SFU even if withdrawn during treatment period.
- group Id
- FG002
- num Subjects
- 213
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 129
- group Id
- FG001
- num Subjects
- 171
- group Id
- FG002
- num Subjects
- 176
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 55
- group Id
- FG001
- num Subjects
- 41
- group Id
- FG002
- num Subjects
- 37
- type
- NOT COMPLETED
- title
- Safety Follow-Up (SFU) Period
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 1
- group Id
- FG002
- num Subjects
- 0
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 2
- group Id
- FG001
- num Subjects
- 2
- group Id
- FG002
- num Subjects
- 2
- type
- Lost to Follow-up
- reasons
- group Id
- FG000
- num Subjects
- 2
- group Id
- FG001
- num Subjects
- 4
- group Id
- FG002
- num Subjects
- 8
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 2
- group Id
- FG002
- num Subjects
- 2
- type
- Administrative reasons
- milestones
- achievements
- comment
- Only participants with CD19+ B-cell counts below baseline level or less than 80 cells/microliter.
- group Id
- FG000
- num Subjects
- 34
- comment
- Only participants with CD19+ B-cell counts below baseline level or less than 80 cells/microliter.
- group Id
- FG001
- num Subjects
- 40
- comment
- Only participants with CD19+ B-cell counts below baseline level or less than 80 cells/microliter.
- group Id
- FG002
- num Subjects
- 51
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 29
- group Id
- FG001
- num Subjects
- 31
- group Id
- FG002
- num Subjects
- 39
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 5
- group Id
- FG001
- num Subjects
- 9
- group Id
- FG002
- num Subjects
- 12
- type
- NOT COMPLETED
- title
- Extended Safety Follow-Up (ESFU) Period
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle